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Abstract
The effects of inhibitors of protein tyrosine kinases (PTKs) on the Cl3 current (IClvol) through volume-regulated anion/
chloride (VRAC) channels whilst manipulating cellular ATP have been studied in mouse fibroblasts using the whole-cell
patch clamp technique. Removal of ATP from the pipette-filling solution prevented activation of the current during osmotic
cell swelling and when the volume of patched cells was increased by the application of positive pressure through the patch
pipette to achieve rates exceeding 100%/min. Equimolar substitution of ATP in the pipette solution with its non-hydrolyzable
analogs, adenosine 5P-O-(3-thiotriphosphate) (ATPQS) or adenylyl-(L,Q-methylene)-diphosphonate (AMP-PCP), not only
supported activation of the current but also maintained its amplitude. The PTK inhibitors, tyrphostins A25, B46, 3-amino-
2,4-dicyano-5-(4-hydroxyphenyl)penta-2,4-dienonitrile and genistein (all at 100 WM), inhibited IClvol in a time-dependent
manner. Tyrphostin A1, which does not inhibit PTK activity, did not affect the current amplitude. The PTK inhibitors also
inhibited IClvol under conditions where ATP in the pipette was substituted with ATPQS or AMP-PCP. We conclude that in
mouse fibroblasts ATP has a dual role in the regulation of the current: it is required for protein phosphorylation to keep
VRAC channels operational and, through non-hydrolytic binding, determines the magnitude of IClvol. We also suggest that
tyrosine-specific protein kinases and phosphatases exhibit an interdependent involvement in the regulation of VRAC
channels. ß 2000 Elsevier Science B.V. All rights reserved.




(VRACs) are widely distributed in mammalian cells
and are believed to be involved in a multitude of
cellular functions including the regulation of cell vol-
ume, cell proliferation, intracellular pH and electrical
processes in the cell membrane. The mechanisms of
their activation are not presently known but the de-
¢nitive stimulus is an expansion in cell volume,
which experimentally is achieved either by osmotic
cell swelling or by cell in£ation through the measur-
ing pipette in the whole-cell patch clamp mode. It is
generally accepted that the same VRACs are acti-
vated by either method [1].
One of the distinct features of the current £owing
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through VRAC channels (IClvol) is its reliance on
the presence of ATP. In whole-cell patch clamp ex-
periments the current is signi¢cantly suppressed
when the pipette-¢lling solutions do not contain
millimolar ATP (reviewed in [2]). ATP is known to
modulate the function of many ion transporters and
channels through a variety of mechanisms that may
or may not require ATP hydrolysis [3]. One of the
major regulatory processes that rely on ATP hydro-
lysis is protein phosphorylation. There is ample evi-
dence, primarily pharmacological in nature, that pro-
tein phosphorylation, both serine/threonine- and
tyrosine-speci¢c, is involved in the activation and/or
regulation of IClvol in various cell types (reviewed in
[1]). Thus, the proposed involvement of tyrosine pro-
tein phosphorylation is supported by observations
that IClvol in dog cardiac myocytes [4], rat astrocytes
[5] and bovine endothelial cells [6] could be sup-
pressed by inhibitors of protein tyrosine kinases
(PTK) or, in bovine chroma⁄n cells [7] and mouse
¢broblasts [8] by inhibitors of protein tyrosine phos-
phatases (PTP). These electrophysiological ¢ndings
are supported by biochemical observations, albeit
limited. An immediate increase in PTK activity fol-
lowing cell swelling has been detected in cardiac my-
ocytes [9] and cardiac ¢broblasts [10], astrocytes [5]
and C6 glioma cells [11]. In the most conclusive ex-
periments to date, a Cl3 current identical to IClvol
has been induced in lymphocytes in the absence of an
increase in cell volume by the intracellular introduc-
tion of the puri¢ed tyrosine kinase p56lck [12]. Exam-
ples of the serine/threonine-speci¢c protein phos-
phorylation involvement are also abundant. Protein
kinase A has been implicated in the regulation of
IClvol in chick heart cells [13], whereas the involve-
ment of protein kinase C in canine colonic smooth
muscle [14], rat brain endothelial cells [15] and guin-
ea-pig cardiac myocytes [16] was recently described.
Yet another kinase, Rho kinase, has been shown to
modulate the current in bovine endothelial cells [17].
On the other hand, several studies raised the pos-
sibility that non-hydrolytic ATP binding alone may
be su⁄cient for the activation of IClvol, without any
need for ATP hydrolysis. This suggestion is based
upon the observation that the current could be in-
duced under conditions where ATP in the pipette
solution was substituted with its non-hydrolyzable
analogs and so it appears that activation of VRAC
channels does not require phosphorylative events
([18^21]; reviewed in [1,2]). Furthermore, it has
recently been suggested that the ATP dependence
of IClvol is conditional on the rate of cell volume
expansion, so that current activation becomes inde-
pendent of ATP if the rate exceeds V65%/min
[18].
The relationship between the two modes of ATP
involvement is not clear at present. The studies sup-
porting either of the hypotheses were carried out on
di¡erent cell types which makes direct comparison
di⁄cult. We attempted to address these issues by
investigating the e¡ects of PTK inhibitors on IClvol
in mouse ¢broblasts whilst manipulating cellular
ATP. Our ¢ndings support the model in which
both (tyrosine) protein phosphorylation and non-hy-
drolytic ATP binding are necessary for the activation
of VRAC channels.
2. Materials and methods
The experiments were carried out on mouse ¢bro-
blasts (LM TK-, ATCC No. CCL-1.3). Cell mono-
layers were cultured at 37‡C in DMEM/F12 medium
mixture supplemented with 10% fetal bovine serum
and antibiotics. For electrical and optical recordings,
cells were plated on 12-mm glass coverslips and cul-
tured for 24^48 h. The coverslips were placed in a
recording chamber mounted on the stage of an
inverted microscope (Zeiss Axiovert 100). The
V500-Wl chamber was continuously perfused with
the control bath solution using a conventional grav-
ity-fed £ow system (V1 ml/min). Whole-cell patch
clamp recordings were performed using the Axo-
patch 200A ampli¢er. Digidata 1200 interface board
and pClamp 6 software (Axon Instruments) were
used to generate voltage-clamp command voltages
and acquire data (50 ms sampling interval). Patch
pipettes were made from thin-walled borosilicate
glass and had resistances between 2 and 5 M6
when ¢lled with the pipette solution; no series resis-
tance compensation was employed. The membrane
conductance, de¢ned as the slope of the I^V charac-
teristics at the reversal potential, was measured every
30 s by ramping the membrane voltage from 360 to
+60 mV (over 2.5 s) relative to a chosen holding
potential [22]. As each cell served as its own control,
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no attempts were made to calculate the current or
conductance densities. The membrane voltage values
were corrected for liquid junction potentials arising
between the pipette or the bath electrode and the
various extracellular solutions. Junction potentials
were measured separately against a 3 M KCl-¢lled
reference pipette [23].
The cells were normally bathed in a solution con-
taining (mM): 130 NaCl, 5 CaCl2, 2 MgCl2, 2.8 KCl
and 10 HEPES, with the pH adjusted to 7.4 with
Tris^OH and the osmolality adjusted to 300 mOsm/
l with mannitol. The hyposmotic solution (150
mOsm/l) used in the regulatory volume decrease
(RVD) experiments, was a 1:1 mixture of the control
bath solution and water. The pipette solution con-
tained (mM): 127 K-aspartate, 16 KCl, 2 MgSO4,
2 ATP, 1 EGTA, 20 HEPES, pH 7.2 with Tris^OH
(285 mOsm/l). The hyperosmotic pipette solution
contained (mM): 140 CsCl, 2 MgSO4, 2 ATP,
1 EGTA, 20 HEPES, pH 7.2 with Tris^OH and
mannitol to obtain an osmolality of 315 mOsm/l.
The osmolality of the solutions was measured with
a Micro-Osmometer model 3MO (Advanced Instru-
ments, Needham Heights, MA, USA).
The PTK inhibitors used in this study were: 3-
ADHD (3-amino-2,4-dicyano-5-(4-hydroxyphenyl)-
penta-2,4-dienonitrile) from Tocris, tyrphostin A1
(AG9, K-cyano-(4-methoxy)cinnamonitrile), tyrphos-
tin A25 (AG82, K-cyano-(3,4,5-trihydroxy)cinnamo-
nitrile), tyrphostin B46 (AG555, K-cyano-(3,4-dihy-
droxy)-N-(3-phenylpropyl)cinnamide) and genistein
(4P,5,7-trihydroxyiso£avone), all from Calbiochem.
Stock solutions of these substances (in DMSO, the
3-ADHD was dissolved in ethanol) were kept at
320‡C and diluted to the required concentrations
immediately prior to their use. The ¢nal concentra-
tion of DMSO or ethanol was 0.1^0.5%. The PTK
inhibitors were applied extracellularly using an appli-
cation pipette (V50 Wm tip) whose tip was posi-
tioned V250 Wm from the patched cell. ATP (adeno-
sine 5-triphosphate, disodium salt) and ATPQS
(adenosine 5P-O-(3-thiotriphosphate), tetralithium
salt) were from Sigma, AMP-PCP (adenylyl-(L,Q-
methylene)-diphosphonate, tetralithium salt) was
from Boehringer Mannheim.
An increase in the volume of patched cells was
induced by short (1^3 s) pulses of positive pressure
(1.3^2.6 kPa) applied through the patch pipette,
under continuous visual control or, in other experi-
ments, by cell swelling during dialysis with the hyper-
osmotic pipette solution. The cell volume was meas-
ured using a video imaging system consisting of a
CCD video camera attached to the microscope
equipped with di¡erential interference contrast optics
and a 40U (NA 0.65) objective lens. Cell images
were collected every 30 s during the 8 min-long re-
cording periods and analyzed o¡-line using the
UTHSCSA ImageTool v. 1.28 program (developed
at the University of Texas Health Science Center at
San Antonio, TX, USA, and available from the In-
ternet by anonymous FTP from maxrad6.uthscsa.
edu). In the cell in£ation experiments the cell images
were ¢rst videotaped and later captured o¡-line into
the computer memory, one per second for 10^20 s
before and after in£ation. Cell images were displayed
on a computer monitor and the cross-sectional area
(CSA) of the soma of single cells was measured by
manually tracing the cell borders. The relative cell
volume changes (V/V0) were calculated using the
equation V/V0 = (test CSA/control CSA)3=2 [24].
All experiments were conducted at room temper-
ature (21^23‡C). Unless otherwise indicated, results
are presented as means þ S.E.M. Statistical compar-
isons were performed using Student’s t-test (Prism
2.01, GraphPad Software, San Diego, CA, USA).
A P-value of less than 0.05 was adopted for statisti-
cally signi¢cant di¡erences.
3. Results
3.1. ATP dependence of IClvol in mouse ¢broblasts
The suppression of IClvol in mouse ¢broblasts by
PTP inhibitors observed in our previous studies [8]
strongly indicated that the functional state of VRAC
channels is controlled by tyrosine-speci¢c protein
phosphorylation. In the present study, we also con-
¢rmed that, as in many other cell types (reviewed in
[1,2]), the amplitude of IClvol in mouse ¢broblasts
decreased dramatically when ATP was removed from
the patch pipette-¢lling solutions. It is important to
emphasize, that this requirement for ATP was ob-
served not only in osmotically-swollen cells but also
in cells whose volume was increased rapidly by in£a-
tion through the patch pipette. This ¢nding contrasts
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with the recently described observation [18], where
the activation of VRAC channels in N1E115 neuro-
blastoma cells became independent of ATP when the
rates of cell volume expansion by cell swelling ex-
ceeded V65%/min. Cell in£ation can yield much
higher rates of cell volume expansion (up to
1000%/min, e.g. [22]) than those achievable during
cell swelling (less than 100%/min, e.g. [18]). In our
experiments, the amplitude of the cell in£ation-in-
duced IClvol was compared in a number of cells
from the same coverslip that were intracellularly dia-
lyzed with 2 mM ATP-containing solution (ATP-
cells) or with ATP-free solution (non-ATP-cells) in
alternate order. The magnitude of cell in£ation was
controlled so as to keep the rates of cell volume ex-
pansion at moderate levels. In both cell groups the
rates were similar, the pooled data averaged
120 þ 3%/min (n = 8), i.e. twice the rate of the fastest
cell swelling reported by Bond et al. [18]. The
increase in cell volume averaged 40% in the ATP-
cells and 60% in the non-ATP-cells (Fig. 1A). The
di¡erence in the amplitude of IClvol in these two cell
groups was very distinct and signi¢cant (P6 0.001):
on average, the volume-regulated Cl3 conductance
was 6.2 þ 2.2 nS (n = 6) in the ATP-cells and
0.1 þ 0.5 nS (n = 6) in the non-ATP-cells (Fig. 1B).
Thus, in contrast to the N1E115 neuroblastoma cells
[18], ATP dependence of IClvol in mouse ¢broblasts
was not compromised by increasing the rate of cell
volume expansion.
We also tested whether IClvol could be activated
when ATP in the pipette solution was replaced with
its non-hydrolyzable analogs, ATPQS or AMP-PCP.
In separate experiments, the average conductance of
in£ation-induced IClvol was 15.4 þ 1.5 nS (n = 8)
when the pipette-¢lling solution contained 2 mM
ATP, and 15.9 þ 1.3 nS (n = 9) when ATP in the pip-
ette solution was replaced with 2 mM ATPQS. Sim-
ilar results were obtained in pair-matched compari-
sons of IClvol in cells from the same coverslips
swollen during intracellular dialysis with hypertonic
(315 mOsm/l) solutions containing either 2 mM ATP
Fig. 1. ATP dependence of IClvol in mouse ¢broblasts. (A) An increase in cell volume caused by a short pressure pulse (arrow) ap-
plied through the measuring pipette in cells dialyzed with 2 mM ATP-containing solution (open circles) or with ATP-free solution
(closed circles). The volume of four cells was measured for each condition. (B) The amplitude of volume-regulated Cl3 conductance
in cells dialyzed with 2 mM ATP (left bar) or without ATP (right bar). The pre-in£ation values of the membrane conductance have
been subtracted from those measured after cell in£ation. (C, D) Comparison of the Cl3 conductance induced by cell swelling during
dialysis with the hyperosmotic (315 mOsm/l) solutions containing either 2 mM ATP (C) or 2 mM AMP-PCP (D).
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or 2 mM AMP-PCP, another non-hydrolyzable ATP
analog. The amplitude of the volume-regulated Cl3
conductance was not signi¢cantly di¡erent
(P = 0.738) in these two groups of cells: 20.5 þ 3.4
nS (n = 8) in the ATP-cells and 22.4 þ 4.4 nS (n = 7)
in the AMP-PCP-cells (Fig. 1C,D).
The above results show that the activation of
IClvol in mouse ¢broblasts requires the presence of
cellular ATP and that under whole-cell conditions,
ATP replacement with its non-hydrolyzable analogs
does not signi¢cantly a¡ect the current. In addition,
the rate of cell volume expansion does not seem to be
a factor in determining the ATP dependence of
IClvol.
3.2. Inhibition of IClvol by PTK inhibitors
Next we asked whether IClvol in mouse ¢broblasts
is a¡ected by inhibitors of PTKs, as this has been
shown in cardiac myocytes [4] and bovine endothelial
cells [6]. This question is of particular interest since,
in our earlier studies [8], we demonstrated that IClvol
in mouse ¢broblasts could be suppressed by PTP
inhibitors. In order to reduce the possibility of
non-speci¢c e¡ects, we tested several PTK inhibitors
with di¡erent modes of action, those that act by
binding to the substrate binding sites (tyrphostins)
and those that act at the ATP binding site (genistein)
of a PTK.
In the experiments on intact cells, tyrphostin A25
(100 WM) e¡ectively suppressed regulatory volume
decrease (Fig. 2A), similar to what we have earlier
observed with PTP inhibitors [8]. The average rate of
cell shrinkage in the presence of tyrphostin A25 was
only 1.38 þ 0.10%/min (3^10 min interval, n = 26),
compared to 4.0 þ 0.5%/min (2^6 min interval,
n = 41) in the control cells. Tyrphostin A25 also in-
hibited, as did all other PTK inhibitors tested, the
IClvol in whole-cell conditions. The drugs were ap-
plied extracellularly 3.5^4.5 min after the activating
stimulus (cell in£ation), when the current amplitude
attained its maximal value. The inhibition seen was
time-dependent. Immediately after the onset of drug
application (within 15^20 s), inhibition was substan-
tially smaller than at later times when it reached sta-
tionary levels. There was also some voltage depen-
dence of the inhibitory e¡ects, such that the inward
currents were inhibited generally less than the out-
ward ones although the di¡erence was signi¢cant
only with tyrphostin A25 (see below). Maximal sup-
pression of the outward (at +25 mV) or the inward
IClvol current (at 395 mV), measured 2 min after
drug exposure, averaged 50 þ 13% versus 51 þ 12%
(n = 8) for 3-ADHD, 56 þ 8% versus 44 þ 8% (n = 8)
for tyrphostin B46 and 55 þ 8% versus 48 þ 7%
(n = 11) for genistein (Fig. 2B). Tyrphostin A1, which
inhibits PTKs only at very high (millimolar) concen-
trations and therefore is commonly used as a nega-
tive control for tyrphostins, at 100 WM produced
much smaller, statistically insigni¢cant inhibition of
IClvol : 7 þ 4% for the outward and 4 þ 8% (n = 11)
for the inward component.
Fig. 2. Suppression of RVD and IClvol with PTK inhibitors. (A) The e¡ect of tyrphostin A25 (100 WM) on cell swelling and subse-
quent shrinkage (RVD) caused by a decrease (at time zero) in osmolality of the bath solution from 300 to 150 mOsm/l. The drug was
added 2 min before the bath change and persisted in the bath for 12 min (open circles, n = 26). Middle curve (closed circles), RVD in
control conditions (no drug, n = 41). (B) The four groups of bars show the degree of reduction in the outward component of IClvol
(measured at +25 mV) at 0.5, 1.0, 1.5 and 2 min of exposure to tyrphostin A1, 3-ADHD, genistein, tyrphostin B46 and tyrphostin
A25, respectively. Each drug was used at 100 WM.
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3.3. Tyrphostin A25 suppressed IClvol in a
voltage-dependent manner
As mentioned earlier, tyrphostin A25 was quite
unlike the other PTK inhibitors tested in this study
due to several de¢nitive features in its block of
IClvol. A characteristic pattern in its inhibition of
the volume-regulated Cl3 current was the rapid on-
set, so that most of the current decrease occurred in
less than 30 s (the time interval between two succes-
sive voltage ramps) (Fig. 3A). This initial phase of
current blockade exhibited pronounced voltage de-
pendence: the inward current was not inhibited at
all, whereas inhibition became progressively stronger
with increasing depolarization once the current re-
versed its direction (Fig. 3B,D). In Fig. 3B two cur-
rent^voltage relationships are compared, one taken
just prior to tyrphostin application (curve 1, see
also Fig. 3A) and the other taken immediately after
application (curve 2). Fig. 3D presents this voltage
dependence as the ratio of both the I^V relationships
shown in Fig. 3B. The initial decrease in the ampli-
tude of the outward current at +25 mV was 46 þ 5%
(n = 18) compared with only 4 þ 2% (n = 18) for the
inward current at 395 mV (Fig. 3C). The di¡erence
is highly signi¢cant, P6 0.0001 (Fig. 3C). With pro-
longation of tyrphostin exposure the di¡erence be-
tween both the outward and inward current inhibi-
tion became less pronounced (curve 3, Fig. 3B) but
remained signi¢cant even after 2 min (Fig. 3C):
57 þ 6% as compared to 21 þ 5% (n = 13). Inhibition
was reversible upon removal of the drug from the
extracellular medium (Fig. 3A, curve 4) and recovery
of the current amplitude was accompanied by com-
plete restoration of the original shape of the I^V
curve (curves 1 and 4, Fig. 3B). These features seen
in the inhibitory e¡ect suggest a substantial contri-
bution of direct inhibition of the VRAC channels by
tyrphostin A25.
Despite the peculiarities of the tyrphostin A25 ef-
Fig. 3. Features in the inhibition of IClvol with tyrphostin A25. (A) Current recording during application of 100 WM tyrphostin A25
(horizontal bar). IClvol was induced by cell in£ation (arrow). The current spikes were caused by symmetrical voltage ramps ( þ 60 mV
from a holding potential of 335 mV). (B) I^V relationships for IClvol recorded immediately prior to drug application (curve 1), after
15^20 s (curve 2) and 2 min (curve 3) of drug exposure and after drug washout (curve 4). The corresponding current spikes in (A)
are marked with these numbers in brackets. (C) Comparison in the degree of suppression of the outward (closed circles) and inward
(open circles) currents at various time points during drug application. Data points are means þ S.E.M. (n = 11^16). (D) Voltage depen-
dence of the fast inhibition shown as the ratio of the I^V characteristics taken immediately before and 15^20 s after drug application
(curves 1 and 2 in B).
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fects, suppression of IClvol in mouse ¢broblasts by
other PTK inhibitors appears to result from their
expected e¡ects on the activity of PTKs. This is sup-
ported by the lack of e¡ect on IClvol by tyrphostin
A1 which is known for its inability to suppress PTK
activity at micromolar concentrations and also by
the fact that tyrphostins B46 and 3-ADHD acted
similarly to genistein, although these drugs inhibit
tyrosine kinases by distinctly di¡ering mechanisms.
Hence, these results support the suggestion that
PTKs and so tyrosine-speci¢c protein phosphory-
lation play an important role in the activation of
the current.
3.4. PTK inhibitors suppress IClvol activated in the
presence of non-hydrolyzable ATP analogs
The suppression of IClvol with the PTK inhibitors
described in Section 3.3 appears to contradict the
earlier observation (see Fig. 1C,D) of no signi¢cant
di¡erence in the amplitude of the current when ATP
in the measuring pipette was replaced with ATPQS or
AMP-PCP, the ATP analogs which do not support
protein phosphorylation. Therefore, we tested
whether the PTK inhibitors would a¡ect IClvol
under conditions where ATP in the pipette solution
is replaced with its non-hydrolyzable analogs. Sur-
prisingly, they did. Fig. 4A shows a current recording
from a representative experiment in which the
‘ATPQS-supported’ IClvol was suppressed with tyr-
phostin B46. Inhibition progressed throughout the
application of the drug, was reversible upon drug
removal and showed no signi¢cant voltage depen-
dence (Fig. 4B). At 100 WM, tyrphostin B46 sup-
pressed the outward current at +25 mV on average
by 58 þ 8% (n = 7). Similarly, tyrphostins B46 and
Fig. 4. E¡ects of the PTK inhibitors on IClvol in the presence of the non-hydrolyzable ATP analogs. (A) Current recording during
application of 100 WM tyrphostin B46 (horizontal bar). The current was induced by in£ation (arrow) of the cell dialyzed with 2 mM
ATPQS-containing solution. The current spikes were caused by þ 60 mV ramps applied every 30 s from a holding potential of 335
mV. (B) I^V relationships taken immediately prior (circles), 30 s (open squares) and 210 s (closed squares) after drug exposure. (C,
D) A similar experiment carried out on another cell dialyzed with 2 mM AMP-PCP. In (C), the amplitude of volume-regulated Cl3
conductance is plotted before and during application of 100 WM tyrphostin B46 (horizontal bar). In (D), I^V relationships taken at
di¡erent times after the onset of drug application are shown.
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A25 both suppressed IClvol activated in the presence
of the truly non-hydrolyzable ATP analog AMP-
PCP. However, this e¡ect appeared to be irreversible
as the decrease in the current in all cells tested con-
tinued even after the PTK inhibitor application was
terminated (Fig. 4C). Whether this is due to the dif-
ferences between the two ATP analogs used (ATPQS
can support protein kinase activity, whereas AMP-
PCP cannot, e.g. [25]) is not clear.
4. Discussion
The role of ATP in the activation of volume-regu-
lated Cl3 channels has been the subject of numerous
recent studies. Two major modes of ATP involve-
ment have been described, namely, the non-hydro-
lytic ATP binding and the support of protein phos-
phorylation (reviewed in [1,2,26]). Whether the
corresponding models for regulation of VRAC chan-
nels are exclusive or they complement each other is
not clear, partly because the principal studies were
carried out on di¡erent cell types. A further compli-
cation arises from a huge di¡erence in the operation-
al levels of ATP: where ATP binding requires milli-
molar ATP concentrations, a 1000-fold less ATP is
su⁄cient for protein phosphorylation [3]. The
present study was designed to clarify the relationship
between the two models by testing some of their
postulates under critical conditions using the same
cell type, mouse ¢broblasts. These cells possess
VRAC channels which are characterized by moder-
ate outward recti¢cation [7,22], have a I3sCl3 per-
meability sequence and do not inactivate at high
positive membrane voltages [8].
The results obtained in this study provide for
several important conclusions. First, they support
the requirement for high levels of cytosolic ATP
for the activation of IClvol (Fig. 1B). Most probably
this role for ATP is related to its non-hydrolytic
binding to VRAC channels or other regulatory pro-
teins because equimolar substitution of ATP in the
pipette solution with its non-hydrolyzable analogs
did not a¡ect the current amplitude (Fig. 1C,D).
This requirement remained in force even with very
high rates of cell volume expansion (s 100%/min)
achieved by the in£ation of cells through the measur-
ing pipette, contrasting with the recently reported
loss of ATP dependence of IClvol at high (s 65%/
min) rates of osmotic cell swelling in N1E115 neuro-
blastoma cells [18]. The underlying di¡erences still
remain unclear: VRACs in di¡erent cell types and
the various methods employed to increase cell vol-
ume, i.e. osmotic cell swelling versus cell in£ation.
Secondly, our results con¢rmed that IClvol in
mouse ¢broblasts can be suppressed by PTK inhib-
itors (Fig. 2). The conclusion that the drugs used
acted by inhibiting PTKs is supported by the obser-
vations that suppression of IClvol was seen with
PTK inhibitors with di¡erent modes of action (tyr-
phostins versus genistein) but not with tyrphostin
A1, the inactive tyrphostin homolog [5,27^29]. This
conclusion is not compromised by the unusual e¡ects
of tyrphostin A25 (Fig. 3) whose action appears to
involve direct inhibition of VRAC channels (possibly
open channel block). The possibility of a non-PTK
site of action for the PTK inhibitors seems much less
likely, although it cannot be completely ruled out.
Although similar e¡ects of PTK inhibitors have pre-
viously been reported for other cell types (see Section
1 for references), it was an unexpected ¢nding be-
cause in our previous study on these same cells we
observed that the current was also suppressed by
inhibitors of PTPs [8]. If tyrosine protein phosphor-
ylation directly regulates VRAC channels, one would
expect inhibitors of PTKs to cause changes in the
current amplitude opposite to those seen with the
inhibitors of PTPs (see, for example, [6]). Therefore,
we suggest that not only tyrosine protein phosphor-
ylation plays an important role in the activation of
Iclvol in ¢broblasts, but PTPs and PTKs are in-
volved at multiple steps in the activation process or
possibly regulate each others activities (e.g. [30]).
The ¢nding that the PTK inhibitors remained ef-
fective when ATP in the pipette solutions was re-
placed with its non-hydrolyzable analogs (Fig. 4)
suggests that protein phosphorylation must have tak-
en place even under these conditions. Since the ATP
analog AMP-PCP is truly non-hydrolyzable and can-
not support protein phosphorylation, one has to con-
clude that the ATP substitution was not complete,
i.e. some residual ATP remained in these dialyzed
cells at levels su⁄cient to support PTK activity.
This suggestion is reasonable from our estimation
of the rate of ATP wash-out in the whole-cell experi-
ments. For the patch pipettes used in this study
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(average access resistance of 5^6 M6), dialysis with
ATP-free solution would cause the cellular concen-
tration of ATP to drop exponentially with a time
constant of V100 s (see [31]). This translates into a
time period of more than 8 min (the recording time
in our experiments) for the cellular ATP level to
decrease from 2 mM to 10 WM. For comparison,
the half-maximal activity of the cAMP-dependent
protein kinase occurs at only 3.1 WM ATP [32].
Even metabolic cell poisoning, which is arguably
the strongest maneuver to deplete cellular ATP,
may not guarantee the removal of micromolar levels
of ATP which is intrinsic to the living cell. It has
been reported that after 1 h of incubation with
2 WM rotenone (inhibitor of respiration) in glucose-
free medium the cellular level of ATP in EL-4 ascites
tumor cells decreased to 4% of the initial level [33].
Similarly, a 90 min poisoning of nasal respiratory
cells or the 16HBE14o3 cells with the respiratory
inhibitor antimycin A (10 WM) and the glycolytic
inhibitor 2-deoxyglucose (10 mM) resulted in only
a 93^97% decrease in ATP content [34]. Thus, the
residual ATP may be as high as 4^7% of its normal
level and be su⁄cient for various protein kinases.
Indeed, the extent of phosphorylation of the so-
dium/hydrogen exchanger, NHE1, was not detect-
ably altered by the acute ATP depletion which
caused a profound inhibition of cation exchange in
transfected ¢broblasts [35]. This problem has to be
recognized for a more cautious consideration of ATP
dependence of IClvol.
In summary, the present study suggests that cellu-
lar ATP a¡ects IClvol in mouse ¢broblasts in two
ways: by supporting protein phosphorylation (at
very low levels) and by non-hydrolytic binding (at
higher levels). The relationship between these two
processes is not clear at this time but ATP binding
seems to be an important determinant of the current
amplitude. Because signi¢cant changes in cellular
ATP are expected to occur only in metabolic stress,
it is reasonable to suggest that non-hydrolytic ATP
binding only becomes operational in pathological
conditions whereas (tyrosine) protein phosphory-
lation is involved in the physiological control of
VRAC channels.
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